Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
the increase in lifespan in Western countries predicts that CNS diseases
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As such, the appropriate size range for DDS is between 100 and 200 nm.”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [24]
In the citing paper
“however, to be able to cross the BBB, the literature indicates that NPs should be smaller than 200 nm [24].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [24]
Citations
Cites
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
Lindgren, M., Hällbrink, M., Prochiantz, A., & Langel, Ü. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01447-4 · Cited by 803
Lin, T., Zhao, P., Jiang, Y., Tang, Y., Jin, H., Pan, Z., He, H., Yang, V. C., & Huang, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b04268 · Cited by 527
Wiley, D. T., Webster, P., Gale, A., & Davis, M. E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307152110 · Cited by 519
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402
The burden of neurological disease in theUnitedStates: A summary report and call to action
Gooch, C. L., Pracht, E., & Borenstein, A. R. (2017) · Annals of Neurology · doi:10.1002/ana.24897 · Cited by 388
Designing super selectivity in multivalent nano-particle binding
Martinez-Veracoechea, F. J., & Frenkel, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105351108 · Cited by 346
Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting
Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306
Research works printed but not linked: 1
- 10.3390/pharmaceutics10010034 · doi:10.3390/pharmaceutics10010034 · Paper page
Cited by
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Scioli Montoto, S., Muraca, G., & Ruiz, M. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587997 · Cited by 652
“Since endocytosis of NPs by the BBB endothelial cells seems to be predominantly mediated by receptors, many efforts have been made with SLN surface functionalization to enhance their CNS availability (Ceña and Játiva, 2018; Kuo et al., 2019; Wang et al., 2019), as discussed in Section 2 for the functionalized angiopep…”
BackgroundHersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
“Furthermore, by increasing the permeability of the BBB, NPs may also result in uptake of undesired toxic substances [79].”
BackgroundApplications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Synergistic Effects Between Metal Nanoparticles and Commercial Antimicrobial Agents: A Review
Ribeiro, A. I., Dias, A. M., & Zille, A. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c03891 · Cited by 276
Jeong, S.-H., Jang, J.-H., & Lee, Y.-B. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00589-5 · Cited by 256
“Some particles with sizes of approximately 200 nm and/or molecules larger than 600 Da may also be able to cross the BBB through mechanisms of clathrinmediated endocytosis or transmembrane diffusion, but to a very limited extent (Ceña and Játiva 2018).”
BackgroundA review on advances of treatment modalities for Alzheimer's disease
Se Thoe, E., Fauzi, A., Tang, Y. Q., Chamyuang, S., & Chia, A. Y. Y. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119129 · Cited by 219
Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review
Indoria, S., Singh, V., & Hsieh, M.-F. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119314 · Cited by 168
Targeting autophagy, oxidative stress, and ER stress for neurodegenerative disease treatment
Esmaeili, Y., Yarjanli, Z., Pakniya, F., Bidram, E., Łos, M. J., Eshraghi, M., Klionsky, D. J., Ghavami, S., & Zarrabi, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.001 · Cited by 179
Georgeous, J., AlSawaftah, N., Abuwatfa, W. H., & Husseini, G. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101332 · Cited by 160
Drug Delivery Across The Blood–Brain Barrier: Recent Advances in The Use of Nanocarriers
Mulvihill, J. J., Cunnane, E. M., Ross, A. M., Duskey, J. T., Tosi, G., & Grabrucker, A. M. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0367 · Cited by 157
Nanotechnology Meets Oncology: Nanomaterials in Brain Cancer Research, Diagnosis and Therapy
Zottel, A., Paska, A. V., & Jovčevska, I. (2019) · Materials · doi:10.3390/ma12101588 · Cited by 158
“Overall, when designing nanoparticles, it should be considered that positively charged nanomaterials with sizes smaller than 200 nm and decorated surface with different ligands are more likely to successfully cross the BBB [93].”
BackgroundNext generation of boron neutron capture therapy (BNCT) agents for cancer treatment
Coghi, P. S., Li, J., Hosmane, N. S., & Zhu, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21964 · Cited by 142
Advances in nanomedical applications: diagnostic, therapeutic, immunization, and vaccine production
El-Sayed, A., & Kamel, M. S. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-06459-2 · Cited by 154
“They can cross the BBB and other physiological barriers (Ceña and Játiva 2018; Zhou et al. 2018), and can kill intracellular and multiple drug-resistant pathogens efficiently (Talukdar et al.”
BackgroundAngiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review
Habib, S., & Singh, M. (2022) · Polymers · doi:10.3390/polym14040712 · Cited by 155
Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics
Shakeri, S., Ashrafizadeh, M., Zarrabi, A., Roghanian, R., Afshar, E. G., Pardakhty, A., Mohammadinejad, R., Kumar, A., & Thakur, V. K. (2020) · Biomedicines · doi:10.3390/biomedicines8010013 · Cited by 133
The blood–brain barriers: novel nanocarriers for central nervous system diseases
Liu, J., Wang, T., Dong, J., & Lu, Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03247-8 · Cited by 160
“The process is divided into two main steps, where the nanoparticles are first adsorbed on the cell membrane and then internalized through energy-dependent pathways[143, 144].”
Pasquale, D. D., Marino, A., Tapeinos, C., Pucci, C., Rocchiccioli, S., Michelucci, E., Finamore, F., McDonnell, L. A., Scarpellini, A., Lauciello, S., et al. (2020) · Materials & Design · doi:10.1016/j.matdes.2020.108742 · Cited by 125
Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer’s and Parkinson’s Diseases
Jagaran, K., & Singh, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22169082 · Cited by 126
“The BBB, a specialized part of the vascular system, is made up of a basal lamina comprising extracellular matrix proteins (laminin, heparan sulphate or collagen), together with endothelial cells, pericytes, astrocyte endfeet, and interneurons [99].”
BackgroundInfluentialMostafavi, E., Zarepour, A., Barabadi, H., Zarrabi, A., Truong, L. B., & Medina-Cruz, D. (2022) · Biotechnology Reports · doi:10.1016/j.btre.2022.e00714 · Cited by 120
“Nanomaterials not only could provide more selectivity and reduce the adverse side-effects, but they can also be used as means for transporting drugs across the BBB [44].”
BackgroundAgrahari, V., Burnouf, P.-A., Burnouf, T., & Agrahari, V. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.008 · Cited by 112
Nanoparticle entry into cells; the cell biology weak link
Griffiths, G. W., Grüenberg, J., Marsh, M., Wohlmann, J., Jones, A. T., & Parton, R. G. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114403 · Cited by 104
Novel concept of exosome-like liposomes for the treatment of Alzheimer's disease
Fernandes, M., Lopes, I., Magalhães, L., Sárria, M. P., Machado, R., Sousa, J. C., Botelho, C., Teixeira, J., & Gomes, A. C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.018 · Cited by 95
“For a therapy that involves the release of a bioactive molecule into the brain, the most important feature is the ability to traverse the BBB.”
BackgroundInfluentialSong, J., Lu, C., Leszek, J., & Zhang, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810118 · Cited by 91
“The initial progress of transcytosis is the uptake of NPs by endocytosis [100].”
BackgroundCrossing the blood–brain barrier with carbon dots: uptake mechanism and in vivo cargo delivery
Seven, E. S., Seven, Y. B., Zhou, Y., Poudel-Sharma, S., Diaz-Rucco, J. J., Kirbas Cilingir, E., Mitchell, G. S., Van Dyken, J. D., & Leblanc, R. M. (2021) · Nanoscale Advances · doi:10.1039/d1na00145k · Cited by 93
Strategies for surface modification of gelatin-based nanoparticles
Saber, M. M. (2019) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2019.110407 · Cited by 94
The Role of Neurovascular System in Neurodegenerative Diseases
Ahmad, A., Patel, V., Xiao, J., & Khan, M. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02023-z · Cited by 105
“Similarly, chemokines and cytokines released by microglia, astrocytes, and pericytes [150, 151] into the perivascular space [152] allow infiltration of leukocytes”
BackgroundElectroconductive Nanobiomaterials for Tissue Engineering and Regenerative Medicine
Mostafavi, E., Medina-Cruz, D., Kalantari, K., Taymoori, A., Soltantabar, P., & Webster, T. J. (2020) · Bioelectricity · doi:10.1089/bioe.2020.0021 · Cited by 94
“This structure, along with the physiological and electrical mechanisms, prevent pathogens and toxins from entering the brain and, in turn, limits the brain uptake of therapeutic compounds.(65) NP-mediated drug delivery has been considered as a method to help drugs cross the BBB.”
BackgroundMethodPinto, M., Silva, V., Barreiro, S., Silva, R. V. D. S., Remião, F., Borges, F., & Fernandes, C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101658 · Cited by 99
Nallasamy, P., Thenmozhi, R., Thajuddin, N., Shanmuganathan, R., Pugazhendhi, A., & Suganthy, N. (2020) · Process Biochemistry · doi:10.1016/j.procbio.2020.01.026 · Cited by 84
Liposomes for the Treatment of Brain Cancer—A Review
Raju, R., Abuwatfa, W. H., Pitt, W. G., & Husseini, G. A. (2023) · Pharmaceuticals · doi:10.3390/ph16081056 · Cited by 90
Novel Therapeutic Delivery of Nanocurcumin in Central Nervous System Related Disorders
Panzarini, E., Mariano, S., Tacconi, S., Carata, E., Tata, A. M., & Dini, L. (2020) · Nanomaterials · doi:10.3390/nano11010002 · Cited by 83
Lipid nanocapsules to enhance drug bioavailability to the central nervous system
Moura, R. P., Pacheco, C., Pêgo, A. P., Rieux, A. D., & Sarmento, B. F. C. C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.042 · Cited by 75
Song, Y. H., De, R., & Lee, K. T. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.103008 · Cited by 81
NDs@PDA@ICG Conjugates for Photothermal Therapy of Glioblastoma Multiforme
Maziukiewicz, D., Grześkowiak, B. F., Coy, E. L., Jurga, S., & Mrówczyński, R. (2019) · Biomimetics · doi:10.3390/biomimetics4010003 · Cited by 69
Targeted nanomedicine: Lessons learned and future directions
Veiga, N., Diesendruck, Y., & Peer, D. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.010 · Cited by 73
Caffeic acid loaded into engineered lipid nanoparticles for Alzheimer's disease therapy
Andrade, S., Pereira, M. D. C., & Loureiro, J. A. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113270 · Cited by 74
Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer’s disease therapy
Andrade, S., Ramalho, M. J., Loureiro, J. A., & Pereira, M. C. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122167 · Cited by 63
Docetaxel-loaded folate-modified TPGS-transfersomes for glioblastoma multiforme treatment
Luiz, M. T., Viegas, J. S. R., Abriata, J. P., Tofani, L. B., Vaidergorn, M. D. M., Emery, F. D. S., Chorilli, M., & Marchetti, J. M. (2021) · Materials Science and Engineering: C · doi:10.1016/j.msec.2021.112033 · Cited by 62
Toxicologic Concerns with Current Medical Nanoparticles
Cheng, T.-M., Chu, H.-Y., Huang, H., Li, Z., Chen, C.-Y., Shih, Y.-J., Whang‐Peng, J., Cheng, R. H., Mo, J.-K., Lin, H., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147597 · Cited by 65
Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives
Ediriweera, G. R., Chen, L., Yerbury, J. J., Thurecht, K. J., & Vine, K. L. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00297 · Cited by 61
Razavi, Z. S., Alizadeh, S. S., Razavi, F. S., Souri, M., & Soltani, M. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125186 · Cited by 65
Mishra, A., Kumar, R., Mishra, J., Dutta, K., Ahlawat, P., Kumar, A., Dhanasekaran, S., Gupta, A. K., Sinha, S., Bishi, D. K., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104694 · Cited by 63
Behavioral effects of zinc oxide nanoparticles on the brain of rats
Rahdar, A., Hajinezhad, M. R., Bilal, M., Askari, F., & Kyzas, G. Z. (2020) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2020.108131 · Cited by 51
Kumarasamy, M., & Sosnik, A. (2021) · iScience · doi:10.1016/j.isci.2021.102183 · Cited by 59
Recent advances in glioma microenvironment-response nanoplatforms for phototherapy and sonotherapy
Li, X., Geng, X., Chen, Z., & Yuan, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106218 · Cited by 52
Kaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 59
Antibody‐Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds
Adhikari, A., & Chen, I. A. (2025) · Small · doi:10.1002/smll.202409635 · Cited by 62
A Focus on “Bio” in Bio–Nanoscience: The Impact of Biological Factors on Nanomaterial Interactions
Cortez‐Jugo, C., Czuba‐Wojnilowicz, E., Tan, A. E. Q., & Caruso, F. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100574 · Cited by 48
Multimodal targeting of glioma with functionalized nanoparticles
Marei, H. E. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02687-8 · Cited by 51
“, transferrin receptor, albumin transporters, glucose transporter 1 (GLUT1), lactoferrin receptor, and folate receptor) [32].”
BackgroundMendonça, M. C. P., Cronin, M. F., Cryan, J. F., & O’Driscoll, C. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.11.003 · Cited by 48
Ahmad, S., & Hafeez, A. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03089-7 · Cited by 53
Vinod, C., & Jena, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.612692 · Cited by 45
Tunneling Nanotubes: A New Target for Nanomedicine?
Ottonelli, I., Caraffi, R., Tosi, G., Vandelli, M. A., Duskey, J. T., & Ruozi, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042237 · Cited by 45
“, BBB or blood–retinal barrier) and/or the accumulation of NMeds only in the target cells [128,129].”
BackgroundJain, D., Hasan, N., Zafar, S., Thakur, J., Haider, K., Parvez, S., & Ahmad, F. J. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104555 · Cited by 47
Protein-based nanoparticles for therapeutic nucleic acid delivery
Eweje, F., Walsh, M. L., Ahmad, K., Ibrahim, V., Alrefai, A., Chen, J., & Chaikof, E. L. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122464 · Cited by 47
Highlights in targeted nanoparticles as a delivery strategy for glioma treatment
Luiz, M. T., Filippo, L. D. D., Tofani, L. B., de Araújo, J. T. C., Dutra, J. A. P., Marchetti, J. M., & Chorilli, M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120758 · Cited by 44
Abla, K. K., Domiati, S. A., Majzoub, R. E., & Mehanna, M. M. (2023) · Gels · doi:10.3390/gels9060491 · Cited by 47
Tincu, C.-E., Andrițoiu, C. V., Popa, M., & Ochiuz, L. (2023) · Polymers · doi:10.3390/polym15193969 · Cited by 50
Turrina, C., Klassen, A., Milani, D., Rojas‐González, D. M., Ledinski, G., Auer, D., Sartori, B., Cvirn, G., Mela, P., Berensmeier, S., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16487 · Cited by 42
“A diameter between 10 and 100 nm is ideal for most applications in this field, avoiding rapid cleaning from the bloodstream and easy uptake through the blood-brain barrier [64,65].”
BackgroundGao, Y., Zhai, L., Chen, J., Lin, D., Zhang, L., Yang, H. F., Yang, R., Mi, L., & Guan, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.010 · Cited by 45
Saleh, S. R., Abd-Elmegied, A., Madhy, S. A., Khattab, S. N., Sheta, E., Elnozahy, F. Y., Mehanna, R. A., Ghareeb, D. A., & Abdel-Monem, N. M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124218 · Cited by 47
Nanomedicines Targeting Glioma Stem Cells
Sabu, A., Liu, T., Ng, S. S., Doong, R., Huang, Y., & Chiu, H. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c03538 · Cited by 47
Croconaine-based nanoparticles enable efficient optoacoustic imaging of murine brain tumors
Liu, N., Gujrati, V., Malekzadeh‐Najafabadi, J., Werner, J., Klemm, U., Tang, L., Chen, Z., Prakash, J., Huang, Y., Stiel, A. C., et al. (2021) · Photoacoustics · doi:10.1016/j.pacs.2021.100263 · Cited by 40
“limiting the uptake of theranostic drugs in the brain [34].”
BackgroundLu, J., Atochina‐Vasserman, E. N., Maurya, D. S., Shalihin, M. I., Zhang, D., Chenna, S. S., Adamson, J., Liu, M., Shah, H. U. R., Shah, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15061572 · Cited by 41
Control of Luminescence and Interfacial Properties as Perspective for Upconversion Nanoparticles
Schroter, A., & Hirsch, T. (2023) · Small · doi:10.1002/smll.202306042 · Cited by 44
de la Torre, C., & Ceña, V. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040190 · Cited by 45
“The BBB is not only a physical barrier, but also a chemical one because of the different degrading and metabolizing enzymes that endothelial cells express, which, combined with the aforementioned, constitute a major obstacle for drug delivery into the brain [27].”
BackgroundSelf-citationAndrade, S., Loureiro, J. A., & Pereira, M. D. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102163 · Cited by 40
“Furthermore, NPs larger than 200 nm hardly cross the BBB [27].”
BackgroundFormulation of Polymeric Nanoparticles of Antidepressant Drug for Intranasal Delivery
Jani, P., Vanza, J. D., Pandya, N., & Tandel, H. (2019) · Therapeutic Delivery · doi:10.4155/tde-2019-0060 · Cited by 41
Iqubal, A., Syed, M. A., Najmi, A. K., Azam, F., Barreto, G. E., Iqubal, M. K., Ali, J., & Haque, S. E. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113464 · Cited by 38
Karavelioğlu, Z., & Çakır-Koç, R. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.023 · Cited by 42
Mehranfard, N., Ghasemi, M., Rajabian, A., & Ansari, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22820 · Cited by 46
Exploring the unexplored avenues of surface charge in nano-medicine
Shah, S., Rangaraj, N., Singh, S. B., & Srivastava, S. (2021) · Colloids and Interface Science Communications · doi:10.1016/j.colcom.2021.100406 · Cited by 39
Madani, F., Morovvati, H., Webster, T. J., Asaadi, S. N., Rezayat, S. M., Hadjighassem, M., Khosravani, M., & Adabi, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-69888-1 · Cited by 42
Wiwatchaitawee, K., Ebeid, K., Quarterman, J. C., Naguib, Y. W., Ali, M. Y., Oliva, C. R., Griguer, C. E., & Salem, A. K. (2022) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00479 · Cited by 35
Kim, J., Um, H., Kim, N. H., & Kim, D. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.01.006 · Cited by 33
“negatively charged molecules have limitations in BBB penetration, and so does our hit compound for practical applications [39,40].”
BackgroundNanotechnology to Overcome Blood–Brain Barrier Permeability and Damage in Neurodegenerative Diseases
Jiménez, A., Estudillo, E., Guzmán‐Ruiz, M. A., Herrera, N., Victoria-Acosta, G., Cortés-Malagón, E. M., & López-Ornelas, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030281 · Cited by 41
Woon, C. K., Hui, W. K., Abas, R., Haron, M. H., Das, S., & Lin, T. S. (2021) · Current Neuropharmacology · doi:10.2174/1570159x20666211217163540 · Cited by 37
“Thus, an appropriate biocompatible nanocarrier fabricated with suitable size, shape and charge, and surface modification corresponding to the targeted site/mechanism of action is essential for AD nanotherapeutics [177].”
Targeting nanoparticles to malignant tumors
Sharma, N., Bietar, K., & Stochaj, U. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188703 · Cited by 40
Kolishetti, N., Vashist, A., Yndart, A., Atluri, V. S. R., Dhar, S., & Nair, M. G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101046 · Cited by 33
Zhou, C., Sun, P., Xu, Y., Chen, Y., Huang, Y., Hamblin, M. H., Foley, L. M., Hitchens, T. K., Li, S., & Yin, K. (2022) · Advanced Science · doi:10.1002/advs.202104986 · Cited by 39
Nanomedicine-based immunotherapy for Alzheimer's disease
Hoque, M., Samanta, A., Alam, S. S. M., Zughaibi, T. A., Kamal, M. A., & Tabrez, S. S. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104973 · Cited by 34
Elkomy, M. H., El‐Ela, F. I. A., Zaki, R. M., Alsaidan, O. A., Elmowafy, M., Zafar, A., Shalaby, K., Abdelgawad, M. A., Omar, H. A., Salama, R., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082095 · Cited by 35
“Interestingly, drug delivery systems smaller than 200 nm diameter have demonstrated a high capacity to circumvent the BBB via endocytosis pathways [73,74].”
BackgroundShin, T. H., Manavalan, B., Lee, D. Y., Basith, S., Seo, C., Paik, M., Kim, S., Seo, H., Lee, J. Y., Kim, J. Y., et al. (2021) · Particle and Fibre Toxicology · doi:10.1186/s12989-021-00433-y · Cited by 32
“In general, transcytosis is initiated by clathrin- and caveolin-mediated endocytosis and escape from the endocytosis vesicle [106].”
BackgroundPhuong, P. T. T., Le, X. T., Kim, H., Kim, H. K., Lee, E. S., Oh, K. T., Choi, H., & Youn, Y. S. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s262690 · Cited by 32
Nanocarriers for effective nutraceutical delivery to the brain
Meenambal, R., & Bharath, M. M. S. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104851 · Cited by 29
Jang, J., & Park, C. B. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c03066 · Cited by 28
Nanotechnology in Stroke: New Trails with Smaller Scales
Toljan, K., Ashok, A., Labhasetwar, V. D., & Hussain, M. S. (2023) · Biomedicines · doi:10.3390/biomedicines11030780 · Cited by 30
Bukchin, A., Sánchez‐Navarro, M., Carrera-Aubesart, A., Teixidò, M., Carcaboso, A. M., Giralt, E., & Sosnik, A. (2020) · Chemistry of Materials · doi:10.1021/acs.chemmater.0c01696 · Cited by 30
Paul, S., Hmar, E. B. L., Pathak, H., & Sharma, H. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90773-6.00004-x · Cited by 31
Turrina, C., Milani, D., Klassen, A., Rojas‐González, D. M., Cookman, J., Opel, M., Sartori, B., Mela, P., Berensmeier, S., & Schwaminger, S. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314743 · Cited by 30
“For the crossing of the blood–brain barrier, similar sizes are favorable [61].”
BackgroundBiomimetic nanotherapeutics for targeted drug delivery to glioblastoma multiforme
Lim, X. Y., Capinpin, S. M., Bolem, N., Foo, A. S. C., Yip, G. W., Kumar, A. P., & Teh, D. B. L. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10483 · Cited by 31
“Studies centered on harnessing the extent and duration of BBB disruption are also paramount as an indefinite opening of the BBB will predispose the brain to infection or drug-induced cerebral toxicity.(46,47) 3.”
BackgroundNanophytomedicines as Therapeutic Agents for Parkinson’s Disease
Burns, J., Buck, A. C., Souza, S. D., Dube, A., & Bardien, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c04862 · Cited by 32
Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance
Behrooz, A. B., Vazifehmand, R., Tajudin, A. A., Masarudin, M. J., Sekawi, Z., Masomian, M., & Syahir, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01017-1 · Cited by 30
Controlling action potentials with magnetoelectric nanoparticles
Zhang, E., Shotbolt, M., Chang, C.-Y., Scott‐Vandeusen, A., Chen, S., Liang, P., Radu, D. R., & Khizroev, S. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.08.008 · Cited by 29
“Furthermore, nanoparticles below a critical size or with the help of specific coatings can cross the blood-brain barrier (BBB) [29 – 31], providing a pathway to non-surgical delivery.”
BackgroundJi, X., Wang, H., Chen, Y., Zhou, J., & Liu, Y. (2019) · AMB Express · doi:10.1186/s13568-019-0869-3 · Cited by 31
Lipid Nanoparticles for Brain Tumor Theranostics: Challenges and Status
Kaur, N., Gautam, P., Nanda, D., Meena, A. S., Shanavas, A., & Prasad, R. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00293 · Cited by 25
Wu, J., Gupta, G. S., Buerki‐Thurnherr, T., Nowack, B., & Wick, P. (2024) · NanoImpact · doi:10.1016/j.impact.2024.100533 · Cited by 27
Recent Advances in Nanocrystals Heralding Greater Potential in Brain Delivery
Mule, S. R., Khairnar, P., & Shukla, R. (2022) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.202200087 · Cited by 23
Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes
Guo, S., & Yi, C. (2023) · Nanotechnology Reviews · doi:10.1515/ntrev-2023-0158 · Cited by 25
Metadata
- Authors
- Ceña, V., & Játiva, P.
- Affiliations
- Unidad Asociada Neurodeath, Universidad de Castilla-La Mancha, Albacete, Spain
- Instituto de Salud Carlos III (ES)
- ORCID
- Játiva, Pablo
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2018-07
- Volume
- 13
- Issue
- 13
- Pages
- 1513-1516
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2868168748
- Semantic Scholar
- f5267cc2f2cb4aee9679939ee9c77f593ddb94ac
- Cited by
- 232
- References
- 21
- Citations by year
- 2026: 14 · 2025: 27 · 2024: 31 · 2023: 47 · 2022: 45 · 2021: 32 · 2020: 21 · 2019: 14 · 2018: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nanomedicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- blood-brain barrier, nanoparticles, nanoparticle delivery, central nervous system disorders, brain drug delivery, neurodegenerative diseases, neuroinflammation
- MeSH terms
- Biological Transport, Blood-Brain Barrier, Central Nervous System, Central Nervous System Diseases, Humans, Drug Delivery Systems, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.